ROYALTY PHARMA PLC- CL A (RPRX)

GB00BMVP7Y09 - Common Stock

30.37  -0.08 (-0.26%)

After market: 30.68 +0.31 (+1.02%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
2.29B
7.87%
2.237B
-2.28%
2.355B
5.25%
2.668B
13.31%
N/AN/AN/AN/A
EBITDA
YoY % growth
N/AN/AN/A2.533B
EBIT
YoY % growth
1.431B
-13.84%
922.9M
-35.49%
1.492B
61.68%
2.129B
42.68%
N/AN/AN/AN/A
Operating Margin
62.49%41.25%63.37%79.80%N/AN/AN/AN/A
EPS
YoY % growth
2.233.67
64.57%
4.38
19.35%
3.84
-12.36%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
0.97
-39.31%
Revenue
Q2Q % growth
678.88M
-0.75%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
637.29M
EBIT
Q2Q % growth
557.13M
16.31%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
1.15
-26.28%
1.030.1211.63%
Q3 2023
Q2Q % growth
0.79
9.72%
0.770.022.45%
Q2 2023
Q2Q % growth
0.84
6.33%
0.820.021.92%
Q1 2023
Q2Q % growth
1.60
166.67%
1.300.3023.19%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
596.068M
5.37%
705.48M-109.412M-15.51%
Q3 2023
Q2Q % growth
536.3M
-6.49%
630.35M-94.05M-14.92%
Q2 2023
Q2Q % growth
538.2M
0.41%
547.32M-9.12M-1.67%
Q1 2023
Q2Q % growth
684M
21.71%
869.96M-185.96M-21.38%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS8.59% 1.82% -1.78% -5.33%
Revenue6.51% -6.31% -0.82% -3.09%